Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 3/20 | 0.58 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.53 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.53 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.51 |
| ▸ | AGXT | P21549 | 1/20 | 0.49 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.49 |
| ▸ | GLS | O94925 | 2/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA4 | P22748 | 1/20 | 0.47 |
| ▸ | CA5A | P35218 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29534459 | 0.86 | CYP2A6 (0.61) | CYP2A6ASIC3LOXL2BCL2L1AGXT | |
| SCHEMBL631264 | 0.86 | CYP2A6 (0.61) | CYP2A6ASIC3LOXL2BCL2L1AGXT | |
| SCHEMBL28666644 | 0.81 | CYP2A6 (0.56) | CYP2A6ASIC3LOXL2BCL2L1AGXT | |
| SCHEMBL29861035 | 0.81 | CYP2A6 (0.56) | CYP2A6ASIC3LOXL2BCL2L1AGXT | |
| SCHEMBL1029348 | 0.81 | CYP2A6 (0.59) | CYP2A6ASIC3LOXL2BCL2L1AGXT | |
| SCHEMBL1260041 | 0.81 | CYP2A6 (0.59) | CYP2A6ASIC3LOXL2BCL2L1AGXT | |
| SCHEMBL11215245 | 0.81 | CYP2A6 (0.59) | CYP2A6ASIC3LOXL2BCL2L1AGXT | |
| SCHEMBL31356469 | 0.81 | CYP2A6 (0.59) | CYP2A6ASIC3LOXL2BCL2L1AGXT | |
| SCHEMBL11221971 | 0.79 | CYP2A6 (0.58) | CYP2A6ASIC3LOXL2BCL2L1AGXT | |
| SCHEMBL7140216 | 0.79 | RAB9A (0.49) | CYP2A6ASIC3LOXL2AGXTADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040121965-A1 | Method of treating resistant tumors | WYETH HOLDINGS CORPORATION (US) | 2004-06-24 | — | — | US | disclosed |
| WO-2004026293-A2 | HEMIASTERLIN DERIVATIVES FOR TREATING RESISTANT TUMORS | WYETH HOLDINGS CORPORATION (US) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040121965-A1 | Method of treating resistant tumors | SLC11A2, VHL, REN | CYP2A6 2950/4885ASIC3 2801/4885LOXL2 758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.